Brief: Enlivex Announces The Dosing Of The First Patient In A Phase I/II Trial Evaluating AllocetraTM In Patients With Thumb Osteoarthritis
24/06/2024 15:09
June 24 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES THE DOSING OF THE FIRST PATIENT IN A
RANDOMIZED, PLACEBO-CONTROLLED PHASE I/II TRIAL EVALUATING
ALLOCETRATM IN UP TO 46 PATIENTS WITH THUMB OSTEOARTHRITIS
Source text for Eikon: ID:nGNX2FLvBT
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment